Translational Development Acquisition CORP

Translational Development Acquisition Corp. (TDAC) has entered into a definitive subscription agreement with Naetas Holding Limited for $50 million in Class A ordinary shares and warrants, a key step towards its business combination with ProLogium.

Translational Development Acquisition Corp. (TDAC) announced ProLogium's filing of a Registration Statement on Form F-4 with the SEC, advancing their de-SPAC transaction.

Translational Development Acquisition Corp. has amended its governing documents to extend the deadline for consummating a business combination up to June 24, 2027, with monthly extensions requiring sponsor deposits.

Translational Development Acquisition Corp. announced the conversion of 4,657,499 Class B ordinary shares into Class A ordinary shares held by its sponsor.

ProLogium, a solid-state battery developer, announced a business combination with Translational Development Acquisition Corp. (TDAC) to list on Nasdaq under the ticker PRLG.

Translational Development Acquisition Corp. secured a non-interest bearing promissory note for up to $2 million from its sponsor, TDAC Partners LLC, for working capital.

Translational Development Acquisition Corp. reports net income of $1.33M for Q1 2026, driven by investment income, while continuing its search for a business combination before its June 2026 deadline.

Translational Development Acquisition Corp. reports increased trust account value and net income, but faces a going concern warning as its business combination deadline approaches.

Translational Development Acquisition Corp. reported a net income of $1.62 million for Q2 2025, driven by dividends from its Trust Account, but faces going concern doubts due to its limited operating cash and upcoming business combination deadline.

Translational Development Acquisition Corp. reports a net income of $1.48 million for the quarter ended March 31, 2025, driven by dividends earned on marketable securities.

Translational Development Acquisition Corp. files an amendment to its 2025 annual report, revising its conclusion on disclosure controls and procedures to 'not effective'.

Translational Development Acquisition Corp. files Amendment No. 1 to its 2025 Form 10-K, primarily addressing controls and procedures.

Translational Development Acquisition Corp. reports its financial results for the year ended December 31, 2024, including a net loss of $71,012 and details of its initial public offering.

ProLogium and TDAC announced a US$50 million primary capital investment commitment from existing shareholders to support their business combination and accelerate battery production.

ProLogium and TDAC announce a $50 million primary capital investment from existing ProLogium shareholders to support their proposed business combination and fund battery production scale-up.

Translational Development Acquisition Corp. (TDAC) has entered into a definitive subscription agreement with Naetas Holding Limited for $50 million in exchange for Class A ordinary shares and warrants, a key step towards its business combination with ProLogium.

ProLogium Holding Inc. announced its upcoming feature on Bloomberg TV's 'Advancements with Ted Danson' to discuss its solid-state battery technology and manufacturing capabilities.

ProLogium and OPmobility have signed a Memorandum of Understanding (MoU) to jointly develop and integrate next-generation solid-state battery modules for electric vehicles.

Prologium Holding Inc. details its advanced solid-state lithium ceramic battery technology, highlighting safety, energy density, and manufacturing scalability in a filing related to its business combination with Translational Development Acquisition Corp.

Translational Development Acquisition Corp. is asking shareholders to approve a 12-month extension to complete its business combination with ProLogium.

Translational Development Acquisition Corp., a blank check company, has filed an amendment to its Form S-1 registration statement for a proposed $150 million initial public offering.

Translational Development Acquisition Corp., a blank check company, has filed an amendment to its S-1 registration statement for a proposed $150 million initial public offering.

Translational Development Acquisition Corp. files for a $150 million IPO to pursue a merger, share exchange, asset acquisition, or similar business combination.

Meteora Capital, LLC, through its managed funds, has disclosed beneficial ownership of 919,000 shares, representing 6.27% of the Class A Common Stock of Translational Development Acquisition Corp.

Linden Capital L.P. and associated entities have filed an amendment to their Schedule 13G, reporting beneficial ownership of Translational Development Acquisition Corp. Class A Ordinary Shares.

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have reported a beneficial ownership of 1,056,879 Class A ordinary shares, representing 7.2% of the outstanding shares in Translational Development Acquisition Corp.

Wolverine Asset Management, LLC and affiliated entities report beneficial ownership of 4.89% of Translational Development Acquisition Corp.'s Class A Ordinary Shares as of June 30, 2026.

Linden Capital L.P. and affiliated entities report beneficial ownership of 950,000 Class A Ordinary Shares, representing approximately 5.5% of the outstanding shares of Translational Development Acquisition Corp.

Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed a Schedule 13G, reporting beneficial ownership of 6.1% of Translational Development Acquisition Corp.'s Class A ordinary shares as of March 31, 2026.